Praxis precision medicines provides corporate update and reports first quarter 2023 financial results

Ulixacaltamide essential tremor end-of-phase 2 meeting with fda scheduled for june 2023 prax-628 phase 1 study results support preclinical profile indicating potential for best-in-class-efficacy for focal epilepsy cash and investments of $85.8 million  as of march 31, 2023 supports runway into 2q24 boston, may 11, 2023 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2023. “each of our four clinical-stage programs has made meaningful progress this year and we anticipate additional value inflecting milestones throughout the pipeline in the coming months,” said marcio souza, president and chief executive officer of praxis.
PRAX Ratings Summary
PRAX Quant Ranking